Robert Kamen
Director/Board Member chez HBM HOLDINGS LIMITED
Profil
Dr. Robert I.
Kamen is a Senior Advisor at Shangbay Capital Management Co. LLC, an Independent Non-Executive Director at Harbour BioMed (Shanghai) Co., Ltd., an Independent Non-Executive Director at HBM Holdings Ltd., an Advisory Partner at Third Rock Ventures LLC and a Member at European Molecular Biology Organization.
He is on the Board of Directors at Harbour BioMed (Shanghai) Co., Ltd., HBM Holdings Ltd., EpimAb Biotherapeutics, Inc., Lycera Corp.
and Shanghai EpimAb Biotherapeutics Co. Ltd.
Dr. Kamen was previously employed as an Independent Director by Neon Therapeutics, Inc., an Independent Director by Jounce Therapeutics, Inc., a Board of Directors by Anchor Therapeutics, Inc., a Board Of Directors by Velocon Sports Inc, a Chairman by BioAssets Development Corp., a President by Abbot Bioresearch Center, Inc., a President by Abbott Bioresearch Center, a President by BASF Bioresearch Corp., and a Senior Vice President-Scientific Affairs by Genetics Institute, Inc. He also served on the board at Opsonic Therapeutics, Inc. and Harbour Antibodies BV.
He received his undergraduate degree from Amherst College and a doctorate degree from Harvard University.
Postes actifs de Robert Kamen
| Sociétés | Poste | Début |
|---|---|---|
| HBM HOLDINGS LIMITED | Director/Board Member | 01/12/2016 |
Harbour BioMed (Shanghai) Co., Ltd.
 Harbour BioMed (Shanghai) Co., Ltd. BiotechnologyHealth Technology Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China. | Director/Board Member | 01/12/2016 |
EpimAb Biotherapeutics, Inc.
 EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Director/Board Member | 01/05/2015 |
Shangbay Capital Management Co. LLC
 Shangbay Capital Management Co. LLC Investment ManagersFinance Shangbay Capital Management Co. LLC (Shangbay Capital) is a venture capital firm founded in 2015. The firm is headquartered in Palo Alto, California. | Consultant / Advisor | 11/03/2021 |
| European Molecular Biology Organization | Corporate Officer/Principal | 01/01/1976 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Consultant / Advisor | 01/01/2010 |
Anciens postes connus de Robert Kamen
| Sociétés | Poste | Fin |
|---|---|---|
| JOUNCE THERAPEUTICS, INC. | Director/Board Member | 03/05/2023 |
| NEON THERAPEUTICS, INC. | Director/Board Member | 06/05/2020 |
Harbour Antibodies BV
 Harbour Antibodies BV Medical/Nursing ServicesHealth Services Harbour Antibodies BV engages in the production of antibodies and VH domains for therapy. The firm develops two types of human immunoglobulin gene transgenic mice such as mice that generate conventional tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). The company was founded by Frank Grosveld in 2006 and is headquartered in Rotterdam, the Netherlands. | Director/Board Member | 01/12/2016 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Robert Kamen
| Harvard University | Doctorate Degree |
| Amherst College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HBM HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 16 |
|---|---|
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
BioAssets Development Corp.
 BioAssets Development Corp. Pharmaceuticals: MajorHealth Technology BioAssets Development Corp. develops, manufactures and markets pharmaceutical products. The company is headquartered in Wellesley, MA. | Health Technology |
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Health Technology |
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |
| European Molecular Biology Organization | |
| BASF Bioresearch Corp. | |
| AbbVie Bioresearch Center, Inc. | |
Harbour Antibodies BV
Harbour Antibodies BV Medical/Nursing ServicesHealth Services Harbour Antibodies BV engages in the production of antibodies and VH domains for therapy. The firm develops two types of human immunoglobulin gene transgenic mice such as mice that generate conventional tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). The company was founded by Frank Grosveld in 2006 and is headquartered in Rotterdam, the Netherlands. | Health Services |
Jounce Therapeutics, Inc.
 Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
| Opsonic Therapeutics, Inc. | |
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Harbour BioMed (Shanghai) Co., Ltd.
Harbour BioMed (Shanghai) Co., Ltd. BiotechnologyHealth Technology Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China. | Health Technology |
Shangbay Capital Management Co. LLC
Shangbay Capital Management Co. LLC Investment ManagersFinance Shangbay Capital Management Co. LLC (Shangbay Capital) is a venture capital firm founded in 2015. The firm is headquartered in Palo Alto, California. | Finance |
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |
| Velocon Sports Inc | |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
